We serve Chemical Name:5-fluoro-2-methylpyridine-3-carbaldehyde CAS:959616-51-4 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
Chemical Name:5-fluoro-2-methylpyridine-3-carbaldehyde
CAS.NO:959616-51-4
Synonyms:5-fluoro-2-methylnicotinaldehyde
Molecular Formula:C7H6FNO
Molecular Weight:139.12700
HS Code:2933399090
Physical and Chemical Properties:
Melting point:N/A
Boiling point:N/A
Density:N/A
Index of Refraction:
PSA:29.96000
Exact Mass:139.04300
LogP:1.34160
Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:
Contact us for information like 5-fluoro-2-methylnicotinaldehyde chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,5-fluoro-2-methylnicotinaldehyde physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,5-fluoro-2-methylnicotinaldehyde Use and application,5-fluoro-2-methylnicotinaldehyde technical grade,usp/ep/jp grade.
Related News: AstraZeneca Plc said on Monday that its cancer drug met the main goal of delaying the progression of a form of lung cancer. 5-fluoro-2-methylpyridine-3-carbaldehyde manufacturer You will find the name and amount of the active ingredient contained in the medicine on the package of OTC (over-the-counter) drugs. 5-fluoro-2-methylpyridine-3-carbaldehyde supplier From basic chemical raw materials to chemical preparations, complex chemical and physical processes are required. The production of chemical raw materials and intermediates concentrates the main synthetic procedures and technical links, which is the prerequisite and important guarantee for the development of the chemical pharmaceutical industry. 5-fluoro-2-methylpyridine-3-carbaldehyde vendor AstraZeneca Plc said on Monday that its cancer drug met the main goal of delaying the progression of a form of lung cancer. 5-fluoro-2-methylpyridine-3-carbaldehyde factory Analysts at Mizuho Americas, who spoke to Lilly’s management this week, said that may well have now changed. “Overall, it sounds like the approval raises new questions for Lilly (as it does for many of us!),” the firm said in a note to clients.
